CMS finalized a four-code complexity-based structure replacing legacy radiation oncology G-codes effective January 1, 2026, consolidating image guidance and treatment delivery under codes 77387, 77402, 77407, and 77412.

Retrospective analysis of pediatric cancer survivors identified low overall CHIP prevalence, with antimetabolite therapy and methotrexate exposure emerging as the strongest treatment-associated signals.

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.

The FDA approved vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy progression, marking the first regulatory approval of a PROTAC drug.

A widely shared r/medicine thread drew candid, self-identified physician commentary on which specialties absorb the most interprofessional scrutiny, with emergency medicine and primary care drawing the heaviest fire.